



## **CHIMERIX TO PRESENT AT 12<sup>th</sup> ANNUAL UBS GLOBAL LIFE SCIENCES CONFERENCE**

**RESEARCH TRIANGLE PARK, NC, September 17, 2010** - Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present a corporate overview at the upcoming 12<sup>th</sup> Annual UBS Global Life Sciences Conference on September 22, 2010 at 3:30 pm ET. The conference is being held at the Grand Hyatt in New York City.

Mr. Moch will discuss the company's antiviral pipeline and technology assets, including CMX001, a broad spectrum antiviral in clinical development for the treatment of double-stranded DNA viruses such as cytomegalovirus, adenovirus, BK virus, JC virus, Epstein-Barr virus and herpes simplex virus; and CMX157, being developed as a potential once-weekly nucleoside analogue against HIV infections.

### **About Chimerix**

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health. The company's lead candidate, CMX001, is in Phase 1 and Phase 2 clinical studies in immunocompromised transplant and cancer patients for the treatment of life-threatening viruses, such as cytomegalovirus, adenovirus and BK virus. CMX001 is also being developed as a biodefense countermeasure in the event of a smallpox release. Chimerix has advanced a second antiviral compound, CMX157, into Phase 1 clinical studies as a potent nucleoside analogue against multi-drug resistant HIV infections. Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, malaria and other global public health needs.

Privately-held, Chimerix has received financing from Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Company and Frazier Healthcare Ventures, as well as significant funding from the National Institute of Allergy and Infectious Diseases. For additional information on Chimerix, please visit <http://www.chimerix.com>.

###

### **CONTACTS:**

Chimerix, Inc.

Kenneth I. Moch, President and Chief Executive Officer, +1.919.313.2961

BCC Partners

Susan M. Pietropaolo or Michelle Corral, +1.201.923.2049 or +1.415.794.8662